The COVID-19 pandemic has placed greater importance on risk management, and has required clinical trial sites, sponsors, and clinical research organizations (CROs) to adopt remote and risk-based quality management (RBQM) methodologies for clinical trial execution to:

• ensure the safety of trial participants
• maintain compliance with good clinical practice
• minimize risks to trial integrity

Many have recognized great improvements in trial execution and operational efficiencies with this adoption, while others are struggling with how to implement an RBQM approach.

Read this white paper to learn the current state of RBQM approaches to providing decentralized clinical oversight, and the value that adopting these approaches brings to sponsors, CROs, sites, and ultimately patients.